Can I Take Calcium with Rezdiffra (Resmetirom)?

What Is Resmetirom and Why Do MASH Patients Often Take Calcium?

Resmetirom is the first FDA-approved pharmacotherapy for non-cirrhotic MASH with moderate-to-advanced fibrosis (F2-F3). It is a liver-directed, selective thyroid hormone receptor beta (THR-beta) agonist. By activating THR-beta in hepatocytes, resmetirom reduces hepatic fat accumulation and fibrogenesis without meaningfully activating cardiac or bone THR-alpha receptors [1].

MASH does not occur in isolation. The condition clusters with metabolic syndrome, type 2 diabetes, and obesity. Each of those conditions independently raises fracture risk through reduced physical activity, poor diet, and sometimes glucocorticoid use [2]. Vitamin D insufficiency is near-universal in patients with significant hepatic fibrosis, and calcium supplements are frequently co-prescribed alongside vitamin D to protect bone mineral density [3].

That clinical reality means a large share of Rezdiffra patients will already be taking calcium carbonate or calcium citrate when they start therapy. Understanding whether that combination is safe is a practical question for prescribers and patients alike.

How Resmetirom Is Absorbed and Metabolized

Resmetirom reaches peak plasma concentration (Tmax) in approximately four hours after oral dosing. It is highly protein-bound (greater than 99%) and undergoes hepatic metabolism primarily via CYP2C8 and, to a lesser extent, CYP3A4 [4]. Biliary excretion is the dominant elimination route. The prescribing information confirms that resmetirom is a substrate of OATP1B1 and OATP1B3 transporters, which is why co-administration with strong OATP1B inhibitors such as cyclosporine is contraindicated [4].

Calcium does not inhibit or induce CYP2C8, CYP3A4, OATP1B1, or OATP1B3 at physiologically achievable concentrations. This is the principal reason a direct pharmacokinetic interaction is not anticipated.

Why Calcium Matters for the Thyroid Pathway

Resmetirom's mechanism involves selective THR-beta agonism, which raises the question of whether calcium's well-established interaction with levothyroxine absorption has any parallel here. Calcium carbonate reduces levothyroxine bioavailability by up to 25% when the two are co-administered, likely through adsorption in the gastrointestinal tract [5].

Resmetirom is not a thyroid hormone. It is a small-molecule receptor agonist that is absorbed independently of the thyroid-hormone transport mechanisms affected by calcium chelation. The levothyroxine-calcium interaction is therefore not directly applicable to resmetirom. Some resmetirom-treated patients are also on levothyroxine for hypothyroidism. For those individuals, the calcium-levothyroxine separation window remains clinically relevant and should not be overlooked.

Is There a Direct Pharmacokinetic Interaction Between Calcium and Resmetirom?

No direct pharmacokinetic interaction has been identified in published literature or the FDA-approved prescribing information for resmetirom [4]. Calcium does not chelate resmetirom in the gut the way it chelates tetracycline antibiotics or bisphosphonates, because resmetirom lacks the polyanionic functional groups that drive those chelation reactions [6].

What the Prescribing Information Does and Does Not Say

The Rezdiffra prescribing information lists specific drug interactions with statins, cyclosporine, and rifampin, reflecting resmetirom's transporter and CYP profile [4]. Calcium is not mentioned. The FDA label does not require dose separation from calcium-containing products.

The absence of a warning is not the same as a blanket guarantee of no effect. No dedicated drug-supplement interaction trial has been conducted with resmetirom and calcium. Clinical pharmacology data from the MAESTRO-NASH trial did not specifically examine calcium co-administration, and that gap in formal study is worth acknowledging [7].

Bisphosphonate Parallel: A Useful Comparator

Bisphosphonates such as alendronate provide a useful comparator. Calcium drastically reduces bisphosphonate bioavailability by forming insoluble complexes in the stomach, which is why all bisphosphonate labels mandate a 30-to-60-minute separation from food and supplements [6]. Resmetirom does not share the phosphonate backbone or the ionic-binding behavior that drives this interaction. The analogy breaks down at the molecular level.

Pharmacodynamic Considerations: Does Calcium Affect Resmetirom's Liver Activity?

Pharmacodynamic interactions occur when two agents act on the same physiological target or pathway. Calcium has no direct effect on THR-beta signaling, hepatic lipid metabolism, or fibrosis pathways that resmetirom targets. No pharmacodynamic interaction is expected.

Cardiovascular Risk: Separating Signal from Noise

A persistent concern in nutrition literature is whether high-dose calcium supplementation raises cardiovascular risk. A 2011 meta-analysis in BMJ (N=12,000 across 11 trials) raised concern that calcium supplementation without co-administered vitamin D increased myocardial infarction risk by approximately 30% [8]. That finding remains contested. A subsequent analysis using the Women's Health Initiative cohort found no significant cardiovascular signal when calcium and vitamin D were given together [9].

MASH itself is a cardiovascular risk factor. Patients enrolled in MAESTRO-NASH had a mean BMI of 35.6 kg/m2 and high rates of dyslipidemia [7]. Prescribers should account for total calcium intake (diet plus supplements) and generally keep supplemental calcium at or below 500 mg per dose, 1,000 mg per day, which is consistent with current National Osteoporosis Foundation guidance [10].

Thyroid Function Monitoring on Resmetirom

Because resmetirom activates THR-beta, it lowers serum TSH in a dose-dependent fashion. In MAESTRO-NASH, TSH suppression was observed and was reversible on discontinuation [7]. Calcium supplements do not independently suppress TSH. If a patient is taking both calcium and levothyroxine alongside resmetirom, periodic TSH monitoring remains appropriate to distinguish drug effects from supplement-related changes in levothyroxine absorption.

MAESTRO-NASH Trial: What the Evidence Actually Shows

The MAESTRO-NASH phase 3 trial enrolled 966 patients with biopsy-confirmed MASH and F1-F3 fibrosis. At 52 weeks, 24.2% of patients receiving resmetirom 100 mg achieved MASH resolution without worsening fibrosis, compared with 9.2% in the placebo group (P<0.001) [7]. Fibrosis improvement by at least one stage occurred in 25.9% of the 100 mg group versus 14.2% of placebo (P<0.001) [7].

The trial did not report supplement use, including calcium, as a pre-specified covariate. The lack of a calcium-specific subgroup analysis means safety conclusions about the combination rest on mechanistic reasoning and general pharmacokinetic principles rather than randomized evidence.

"Resmetirom represents a meaningful advance for patients with MASH and moderate-to-advanced fibrosis, a population with very limited treatment options," the FDA stated in its March 2024 approval communication [1]. That statement underscores the clinical weight now placed on resmetirom and the importance of avoiding unnecessary supplement interactions that might discourage patients from adhering to therapy.

Practical Dosing Guidance: How to Take Calcium and Rezdiffra Together

The following separation framework is based on resmetirom's four-hour Tmax window, the calcium-levothyroxine separation precedent, and general principles of oral bioavailability management. It has not been validated in a dedicated clinical trial.

Recommended Timing Protocol

Take resmetirom first thing in the morning with food, as the prescribing information directs [4]. Wait at least two hours before taking calcium carbonate, or take calcium in the evening if once-daily dosing is preferred. Calcium citrate is less dependent on gastric acid for absorption than calcium carbonate and may be better tolerated at any separation interval, particularly in patients on proton-pump inhibitors [11].

A practical schedule for a typical patient:

• 7:00 AM: Resmetirom 80 mg or 100 mg with breakfast
• 12:00 PM (or later): Calcium citrate 500 mg with lunch or a snack
• Evening (optional second dose): Calcium citrate 500 mg with dinner if total daily need is 1,000 mg

Splitting calcium into two 500 mg doses also improves fractional absorption. The gut absorbs roughly 36% of a 300 mg calcium dose but only about 28% of a 1,000 mg dose taken at once [10].

Vitamin D Co-Administration

Most calcium supplements are formulated with vitamin D3 (cholecalciferol). Vitamin D is fat-soluble and is not expected to interact with resmetirom's absorption or metabolism. Taking vitamin D with the evening calcium dose avoids any theoretical overlap with the morning resmetirom dose entirely.

Forms of Calcium That Matter

| Calcium Form | Acid Required for Absorption | Best Taken | |---|---|---| | Calcium carbonate | Yes | With food, 2+ hours from resmetirom | | Calcium citrate | No | With or without food; more flexible timing | | Calcium phosphate | Partial | With food preferred |

Monitoring Parameters When Taking Both Agents

Resmetirom's prescribing information requires liver enzyme monitoring at baseline, 4 weeks, 12 weeks, and 24 weeks, then periodically thereafter [4]. This schedule is not altered by calcium co-administration.

Labs to Watch

Patients with MASH on resmetirom should have the following tracked:

• ALT and AST: Resmetirom can cause transaminase elevations. Interrupt therapy if ALT exceeds three times the upper limit of normal with symptoms, or five times without symptoms [4].
• TSH: Check at baseline and any time symptoms of thyroid dysfunction appear.
• Serum calcium: Not required specifically for the resmetirom-calcium combination, but appropriate if a patient is receiving high-dose calcium (above 1,500 mg/day) or has a history of hypercalcemia or nephrolithiasis [11].
• 25-hydroxyvitamin D: Low levels are common in MASH and contribute to bone loss. A target serum level of 30 ng/mL or above is reasonable per Endocrine Society guidelines [12].

Bone Mineral Density Considerations

MASH-related liver inflammation and metabolic dysfunction reduce osteoblast activity. A cross-sectional study published in the Journal of Clinical Endocrinology and Metabolism found that patients with NAFLD (the earlier terminology for MASH) had significantly lower lumbar spine bone mineral density than matched controls, with an odds ratio of 1.43 for osteopenia (P<0.05) [3]. Adequate calcium and vitamin D intake is therefore not merely a general health recommendation for this population; it addresses a specific disease-related risk.

The Endocrine Society recommends 1,000 to 1,200 mg of total daily calcium (diet plus supplements) for adults over 50, with no more than 500 mg per supplemental dose [12].

Who Should Be Most Cautious About This Combination?

Most patients can take calcium and resmetirom together without concern, provided they separate doses by two hours. A smaller group warrants additional attention.

Patients on Concurrent Levothyroxine

Resmetirom suppresses TSH. Calcium reduces levothyroxine absorption. A patient taking all three agents faces additive complexity in thyroid monitoring. Levothyroxine should be taken 30 to 60 minutes before calcium and at least two hours before or after resmetirom to preserve its absorption [5]. TSH should be checked 6 to 8 weeks after any change in calcium dose in these patients.

Patients With Chronic Kidney Disease

CKD patients often have disordered calcium and phosphate metabolism. Resmetirom has not been formally studied in stage 4 or 5 CKD. The prescribing information notes that pharmacokinetics in severe renal impairment have not been evaluated [4]. Adding high-dose calcium in a CKD patient already at risk for hypercalcemia and vascular calcification requires nephrologist input, independent of the resmetirom question.

Patients Taking Statins

Resmetirom's label warns that it increases statin plasma exposure via OATP1B inhibition. Calcium does not share this mechanism. However, many MASH patients are on statins for cardiovascular risk reduction, and prescribers should ensure statin doses comply with the resmetirom label's statin-specific guidance before adding any new supplement [4].

What to Do If You Are Already Taking Both

Stop neither agent without speaking to your prescriber. The combination is not contraindicated. Adjust the timing of calcium so that it is taken at least two hours after the morning resmetirom dose, or shift it entirely to an evening dose. Tell your prescribing clinician that you are taking calcium so it can be documented and so any TSH monitoring can account for absorption effects if levothyroxine is also part of your regimen.

At your next scheduled liver enzyme check (week 4, 12, or 24 of therapy), confirm that ALT and AST remain stable. No extra labs are required specifically for the calcium-resmetirom combination in otherwise healthy MASH patients.

The Endocrine Society's 2012 clinical practice guideline on vitamin D states: "Patients with fat malabsorption syndromes and obesity may need 2 to 3 times higher doses of vitamin D to satisfy the body's vitamin D requirement," a principle that extends to patients with significant hepatic steatosis [12]. Ensuring adequate vitamin D alongside calcium is at least as important as the timing question.